Foundayo Medication Guide reissued with the 7-day missed-dose restart instruction

Eli Lilly has reissued the patient Medication Guide for Foundayo (orforglipron), the once-daily oral GLP-1 tablet, with document number OFG-0002-MG-20260729 ^[1]. The update gives patients specific, plain-language instructions for missed doses that were not spelled out this clearly before.

The guide tells patients to take a missed dose of Foundayo as soon as possible, but never to take two doses in the same day and never to take more than one tablet in a 24-hour period ^[1]. If a patient misses doses for seven or more days in a row, the guide instructs them to call their healthcare provider to talk about how to restart treatment, rather than simply resuming the same dose on their own ^[1].

Foundayo is taken once a day, by mouth, with or without food, and tablets must be swallowed whole and not broken, crushed, or chewed ^[1]. The drug comes in several strengths — 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg — reflecting a dose-escalation schedule typical of GLP-1 medicines, where the dose is raised in steps over time ^[1]. That step-up structure is likely why a week or more of missed doses prompts a check-in with a provider rather than an automatic restart at the same dose.

The guide repeats other core safety information Lilly has attached to orforglipron since its approval, including a boxed-style warning about possible thyroid tumors seen in rodent studies, and a instruction not to use Foundayo if a patient or family member has had medullary thyroid carcinoma or has Multiple Endocrine Neoplasia syndrome type 2 ^[1]. It also warns against combining Foundayo with other GLP-1 receptor agonist medicines, and lists common side effects such as nausea, stomach pain, constipation, diarrhea, and headache ^[1].

Why it matters for patients

Missing doses is common with any daily medicine, and GLP-1 drugs in particular are dosed carefully because the body needs time to adjust to each increase. The reissued guide gives patients a specific, memorable threshold — seven consecutive missed days — for when to stop guessing and call a healthcare provider instead of restarting on their own ^[1]. According to the development summary, Foundayo is currently the only marketed GLP-1 medicine with this specific seven-day reescalation trigger written into its patient guide, which means people switching between GLP-1 products, or those used to the instructions on Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound, should not assume the same missed-dose rule applies across drugs ^[1].

For patients taking Foundayo, the guide also reinforces basic safety points: no doubling up on a missed dose, no more than one tablet per day, and prompt reporting of severe or persistent stomach symptoms, signs of low blood sugar, or symptoms that could suggest a thyroid problem, such as a neck lump, hoarseness, or trouble swallowing ^[1]. The guide also notes that oral birth control pills may not work as well while on Foundayo, and that a healthcare provider may recommend a different birth control method during the first 30 days of treatment and for 30 days after each dose increase ^[1].

What happens next

The Medication Guide is dated with an FDA-approval reference of OFG-0002-MG-20260729 ^[1]. The sources provided do not say whether pharmacies are required to distribute the updated version immediately or on what timeline patients already taking Foundayo will receive it. It is not yet known from the available material whether Lilly plans further changes to the missed-dose instructions or whether other GLP-1 manufacturers will adopt a similar restart threshold.